Cosmetics,
Journal Year:
2024,
Volume and Issue:
11(5), P. 148 - 148
Published: Aug. 27, 2024
Androgenetic
alopecia
(AGA)
is
the
most
common
form
of
hair
loss,
significantly
affecting
both
men
and
women
worldwide.
Characterized
by
progressive
thinning
AGA
primarily
mediated
dihydrotestosterone
(DHT).
Recent
research
has
identified
numerous
single-nucleotide
polymorphisms
(SNPs)
associated
with
AGA,
particularly
in
genes
involved
androgen
metabolism,
prostaglandin
pathways,
vasodilation.
These
genetic
markers
offer
insights
into
pathophysiology
potential
therapeutic
targets.
Pharmacogenetics,
study
how
variations
influence
drug
response,
holds
promise
for
personalized
treatment.
Identifying
SNPs
that
affect
efficacy
treatments
like
minoxidil
finasteride
enables
development
tailored
strategies.
For
instance,
variants
SRD5A2
gene,
which
affects
DHT
can
predict
responsiveness
to
5-alpha-reductase
inhibitors.
Beyond
pharmacogenetics,
RNA
interference
(RNAi)
technologies,
e.g.,
small
interfering
RNAs
(siRNAs),
present
new
avenues.
Studies
have
shown
RNAi-based
targeting
receptors,
promoting
growth
models.
Integrating
pharmacogenetic
clinical
practice
transform
management,
enhancing
treatment
patient
outcomes.
In
conclusion,
are
crucial
developing
while
emerging
RNAi
technologies
promising
interventions.
advancements
represent
significant
steps
toward
more
effective
individualized
therapies.
Journal of Cosmetic Dermatology,
Journal Year:
2024,
Volume and Issue:
23(11), P. 3767 - 3773
Published: July 22, 2024
Androgenetic
alopecia
(AGA)
is
common.
While
topical
minoxidil
remains
the
only
FDA-approved
therapeutic
for
AGA,
its
efficacy
limited
in
stimulating
clinically
significant
hair
regrowth
over
longer
term.
Oral
minoxidil,
which
used
off-label,
a
promising
alternative;
however,
effectiveness
and
underlying
mechanisms
warrant
further
investigation.
To
elucidate
site
of
action
infer
physiological
responses
to
oral
patients
with
AGA.
Forty-one
AGA
underwent
6
months
low-dose
treatment.
Minoxidil
sulfotransferase
(SULT)
activity
was
assayed
plucked
scalp
follicles.
The
primary
outcome
growth
after
treatment
minimum
months,
secondary
SULT
After
treatment,
26
(63.4%)
experienced
clinical
improvement
symptoms.
response
rate
higher
men
(19/26
[73.1%])
than
women
(6/15
[40.0%]).
Patients
low
follicle
demonstrated
those
high
enzyme
(85%
vs.
43%,
p
=
0.009).
Our
findings
indicate
that
within
follicles
associated
favorable
therapy
Further
elucidation
could
significantly
improve
personalized
approaches
through
improved
patient
selection
rational
design
adjuvant
treatments.
Journal of Nanobiotechnology,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Feb. 27, 2025
Androgenetic
alopecia
(AGA),
a
chronic
and
progressive
disease,
significantly
impacts
the
patients'
social,
emotional,
mental
well-being.
Current
treatment
for
AGA
are
mainly
limited
by
drug
side
effects
stratum
corneum
(SC)
barrier
of
scalp.
To
address
these
issues,
we
developed
microneedle
(MN)
system
loaded
with
black
phosphorus
nanosheets
(BP)
encapsulating
baicalin
(BA),
natural
ingredient,
effective
AGA.
We
first
fabricated
BP-BA
based
on
BP
properties
high
loading
capacity
excellent
photothermal
conversion
efficiency.
Upon
635
nm
laser
irradiation,
demonstrated
efficient
to
mild
thermal
~
42
°C.
This
effect
controlled
BA's
stimuli-responsive
release,
enhanced
cellular
uptake,
effectively
modulated
gene
expression
in
dihydrotestosterone-treated
human
dermal
papilla
cells,
downregulating
negative
regulators
such
as
SRD5A2,
AR,
DKK1,
TGFB1,
while
upregulating
positive
like
CTNNBIP1
VEGFA.
Furthermore,
encapsulated
MN
fabricating
BP-BA@MNs
overcome
SC
barrier.
Compared
without
irradiation
penetration
into
subcutaneous
area
accumulation
at
follicular
site.
Importantly,
synergistic
efficacy
against
testosterone-induced
vivo
through
combining
BA
chemotherapy,
BP-mediated
therapy,
delivery,
well
good
biocompatibility
biosafety,
underlying
mechanism
was
elucidated
terms
microenvironment
reconstruction.
is
promising
approach
targeted
providing
multifunctional
strategy
addressing
clinical
needs
anti-AGA.
Expert Opinion on Drug Discovery,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 3, 2025
Introduction
Androgenetic
alopecia
(AGA)
is
the
most
common
cause
of
hair
loss
worldwide.
The
significant
psychological
and
social
impact
AGA
continues
to
drive
demand
for
more
effective
treatments
beyond
limited
options
currently
available.
Chinese Medical Journal,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 17, 2025
Abstract
Background:
Topical
finasteride
is
a
novel
treatment
for
men
with
an
androgenetic
alopecia
(AGA).
This
study
aimed
to
evaluate
the
efficacy
and
safety
of
topical
spray
solution
in
Chinese
AGA.
Methods:
randomized,
double-blind,
placebo-controlled,
phase
III
trial
enrolled
270
individuals
AGA
from
16
sites
across
China
between
December
2021
March
2023.
The
participants
were
randomized
at
ratio
2:1
receive
either
or
placebo
once
daily
24
weeks.
primary
endpoint
was
change
baseline
target
area
(0.903
cm
2
area)
hair
count
week
24.
secondary
endpoints
12,
terminal
weeks
12
24,
width
24;
improvement
vertex
growth
assessed
by
investigator
patient-assessed
scores
on
Male
Hair
Growth
Questionnaire
Results:
A
total
251
completed
study.
Compared
group,
significantly
higher
(
P
<0.05),
although
it
only
numerically
=
0.0688).
Significant
differences
favoring
over
observed
<0.05)
<0.01).
greater
group
vs.
generally
safe
well-tolerated.
Conclusions:
In
AGA,
increased
showed
good
tolerability
profile
during
24-week
period.
Clinical
Trial
Registration:
Clinicaltrials.gov
identifier:
NCT05135468.
